{"id":63174,"date":"2026-05-28T19:03:02","date_gmt":"2026-05-28T17:03:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/"},"modified":"2026-05-28T19:03:02","modified_gmt":"2026-05-28T17:03:02","slug":"aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","title":{"rendered":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine"},"content":{"rendered":"
\n

\nSLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects<\/b><\/p>\n

<\/a>
<\/a><\/p>\n

SEATTLE–(BUSINESS WIRE)–The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo.<\/p>\n

\nCurevo\u2019s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI\u2019s proprietary SLA-SE adjuvant. The acquisition underscores the growing recognition of next-generation adjuvants that can deliver improved tolerability and strong immune responses.<\/p>\n

\n\u201cSLA-SE represents a significant advancement in adjuvant technology, designed to elicit robust T-cell immunity with a favorable safety profile,\u201d said Keeley Foley, CEO of AAHI. \u201cWe are thrilled that this technology, developed at AAHI, is now positioned to reach people through Lilly\u2019s world-class development and commercial capabilities.\u201d<\/p>\n

\nImportantly, AAHI retains rights to license and develop SLA-SE adjuvant for uses outside the shingles (varicella zoster virus) vaccine field. This includes in combination with other antigens for a wide range of infectious diseases, cancer vaccines, and additional indications.<\/p>\n

\nFor more information about AAHI and its work, visit www.aahi.org<\/a>.<\/p>\n

\nAbout Access to Advanced Health Institute (AAHI)<\/b><\/p>\n

\nAAHI is a Seattle-based nonprofit biotech research institute focused on translating high-impact science into affordable, effective, and accessible vaccines. With a global footprint including operations in the United States, England, and South Africa, AAHI collaborates with partners worldwide to combat infectious diseases and improve health equity. For more information, visit https:\/\/www.aahi.org\/<\/a> or contact us at https:\/\/www.aahi.org\/contact\/<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Casey Felipe, Director, Operations & Business Development
\n
Access to Advanced Health Institute
\n
Email: info@aahi.org<\/a>
Phone: 206.381.0883<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects SEATTLE–(BUSINESS WIRE)–The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-63174","format-standard","category-industry"],"yoast_head":"\nAAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects SEATTLE–(BUSINESS WIRE)–The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T17:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine\",\"datePublished\":\"2026-05-28T17:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/\"},\"wordCount\":304,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260528416038\\\/en\\\/2817769\\\/22\\\/Dark_Tall.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/\",\"name\":\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260528416038\\\/en\\\/2817769\\\/22\\\/Dark_Tall.jpg\",\"datePublished\":\"2026-05-28T17:03:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260528416038\\\/en\\\/2817769\\\/22\\\/Dark_Tall.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260528416038\\\/en\\\/2817769\\\/22\\\/Dark_Tall.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend","og_description":"SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects SEATTLE–(BUSINESS WIRE)–The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo. Curevo\u2019s lead ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-28T17:03:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine","datePublished":"2026-05-28T17:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/"},"wordCount":304,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","url":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/","name":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg","datePublished":"2026-05-28T17:03:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260528416038\/en\/2817769\/22\/Dark_Tall.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63174"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63174\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}